Shots:

• An American investment firm, OrbiMed Advisor is a prominent name when it comes to healthcare investments. The company boasts a robust portfolio of more than 180 companies, including AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies, among others
• In 2023, OrbiMed invested in 38 funding rounds; 11, 6, 9 & 12 every quarter across 2023 respectively
• For a detailed report on all the investments, reach out to us at connect@pharmashots.com

OrbiMed Advisor

Founded in 1989, Orbimed Advisor is a global healthcare investment firm, led by 21 partners. The company's investment portfolio ranges from start-ups to large multinational corporations through a range of private equity funds, public equity funds, and royalty and credit funds. Headquartered in New York City, Orbimed has offices in prime geographic locations like London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

The company mainly focuses on the biotechnology and healthcare sectors. In addition to providing funds, Orbimed provides team resources to develop a company from its roots. Orbimed boasts a robust portfolio with more than 180 companies in it, including AbCellera, Acelyrin, Actus Medical, Adaptive Biotechnologies, and so on.

In 2023, OrbiMed made significant investments in biopharma companies, including Odyssey Therapeutics Inc., Iambic Therapeutics Inc. (previously Entos), ADARx Pharmaceuticals Inc., and Caris Life Sciences Inc. Moreover, OrbiMed made a fair share of its investments in devices, diagnostics, manufacturing & service. The firm invested in a wide range of technologies, such as antibodies, artificial intelligence (AI)/machine learning (ML), cell therapy, gene therapy, peptides, radiation/radiotherapy, small molecules, RNA, and so on. OrbiMed made a substantial share of investments in the companies producing small molecules and Artificial Intelligence (AI) / Machine Learning (ML) 

Out of total investments by OrbiMed in 2023, 23.6% of the investments were made under series A financing, whereas other major investments were made in the PIPE and series B rounds. The top 3 investments made by OrbiMed were as follows: 

1. Debt/Loan worth $400M to Caris Life Sciences Inc. 
2. Series C funding worth $200M to ADARx Pharmaceuticals Inc.
3. Series B funding worth $200M to Upstream Biosciences Inc.

In 2023, OrbiMed participated in 38 investment rounds, including 7 PIPE, 1 seed, 9 series A, 7 series B, 4 series C, and 1 series D round. The investments also include 5 loans/debt and 4 private investments.

The table below depicts the top 5 funding rounds out of the 38 investments made by OrbiMed Advisors in 2023:

Note: (For a complete report, reach out to us at connect@pharmashots.com with the subject line "OrbiMed Advisors Data" or for early access to complete data for future reports and analysis register here: https://forms.office.com/r/VwFu6aUm80)

Related Post: Know Your Investor: OrbiMed Advisors